Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients
Condition(s):Hepatocellular CarcinomaLast Updated:September 24, 2021Unknown status
Hide Studies Not Open or Pending
Condition(s):Hepatocellular CarcinomaLast Updated:September 24, 2021Unknown status
Condition(s):Intrahepatic CholangiocarcinomaLast Updated:March 31, 2016Unknown status
Condition(s):Advanced Hepatocellular CarcinomaLast Updated:March 29, 2016Unknown status
Condition(s):Primary Hepatocellular Carcinoma; Portal Vein ThrombosisLast Updated:May 24, 2023Not yet recruiting
Condition(s):Hepatocellular Carcinoma Non-resectableLast Updated:August 14, 2023Recruiting
Condition(s):Hepatocellular CarcinomaLast Updated:October 30, 2020Completed
Condition(s):Hepatocellular Carcinoma; Portal Vein Occlusion; Tumor ThrombusLast Updated:March 3, 2022Unknown status
Condition(s):Hepatocellular CarcinomaLast Updated:January 12, 2024Recruiting
Condition(s):Hepatocellular Carcinoma Non-resectableLast Updated:May 31, 2023Recruiting
Condition(s):HepatoCellular CarcinomaLast Updated:October 22, 2020Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.